Early diagnosis and treatment of stomach cancer still needs to be strengthened, and the dawn of immunotherapy has been dawned

In autumn and October, as the weather cools down, the appetite naturally warms up.
pay attention to the "people to eat for the day" Chinese in autumn has a "paste autumn" custom.
old saying that autumn is good, winter disease does not look for, indeed, eating is a learning.
Know how to eat, will eat, ensure healthy eating habits, can better protect the stomach health, and eating wrong will cause a lot of problems, "eat out of the disease" mostly occurs in the stomach, from old stomach disease to stomach cancer, when several stomach cancer is the most dangerous.
according to the latest cancer statistics, stomach cancer has become the second largest cancer in China after lung cancer.
, the epidemiological status quo of stomach cancer in China can be summed up in three words: large base, late stage, poor survival.
prevention and treatment requires two hands, on the one hand to strengthen prevention and early screening, on the other hand, late-stage innovative treatment is imperative.
stomach discomfort early medical treatment advanced stomach cancer bitter helpless China has the world's largest group of stomach cancer patients, while the incidence rate is much higher than the world average, ranking among the world's leading.
2018, China will have 456,000 new cases of stomach cancer and 390,000 deaths, accounting for 44% and 50% of the global total, respectively.
the burden of such diseases, Professor Li Jin pointed out that China's gastric cancer cure rate and lack of control is a particular problem in the future.
, about 80% of patients with stomach cancer are terminally ill when diagnosed, and there are few alternative treatment options and limited efficacy.
this factor directly contributes to the overall survival rate of gastric cancer patients in China: according to the National Cancer Center in 2018, the five-year survival rate of gastric cancer patients in China is only 36%.
the main cause of high incidence of stomach cancer in China is related to eating habits.
the most common pathogenic factor, helicobacter pyridobacteria prevention on the meal-between system put forward requirements.
In addition, stomach cancer was more common in middle-aged and elderly groups in the past, the incidence rate increased with age, but from the clinical data in recent years, three meals irregular, love of "heavy taste", smoking, drinking and other issues have caused the trend of growing stomach cancer younger.
Li Jin said that the treatment of the disease, stomach cancer, the unsophoned doctor is their own.
if abnormal conditions such as stomach discomfort or weight loss are found, they should seek medical attention as soon as possible, and high-risk groups should have regular gastroscopy to detect and treat them as soon as possible.
advanced stomach cancer is the number one problem of all solid tumors.
Shen Lin admitted: "Previously said 'chemotherapy chemotherapy, one on it', in fact, represents a face of the vast majority of patients with advanced stomach cancer helpless."
After losing the chance of a surgical cure, chemotherapy was previously only available, and chemotherapy drugs were limited in efficacy, and even when developed into a new chemotherapy programme, it usually resulted in less than a year of survival benefits, so to this point often meant that the patient's life entered the countdown."
gastric cancer research has experienced a thousand sails of first-line innovation finally taste sweetness based on stomach cancer difficulties, in recent years, the exploration of targeted innovative treatment is increasing, but its development is not plain sailing.
E.e., targeted treatment for stomach cancer, for example, has not been successful in the field of breast cancer, but only one drug has been approved in the field of stomach cancer, and the efficacy has been short-lived.
," says Professor Shen Lin.
not only that, BUT2 targets a very limited population of Chinese patients, only about 13%-14%.
faced with the huge unseedited needs of the vast majority of HER2-negative patients, the researchers explored the immunotherapy field of the present heat, from the therapeutic stage after the failure of standard chemotherapy to the initial treatment phase.
small achievements, but compared with the full success of lung cancer immunotherapy, the path of immune exploration of stomach cancer is much less aggressive.
Generally speaking, under ethical review requirements, the development of new drugs requires clinical trials from people who are unable to perform conventional treatments, so third- and back-line treatments are the first step in exploration before they can develop into second- and first-line treatments.
gastric cancer immunotherapy in the third-line research after the efficacy and safety certification, the second-line defeat, and then the researchers still diligently continue to move forward, carried out a series of first-line research, but never ushered in good news.
", but no one would deny that PD-1 and PD-L1 inhibitors are bound to be effective in stomach cancer.
", Professor Shen Lin remains confident.
fact, she is also the leading Chinese researcher in the first-line treatment of stomach cancer immunotherapy CheckMate-649.
is that immunotherapy is finally seeing the light of day.
Shen Lin, a professor at the University of Hong Kong, said it had been a "harvest year" for digestive cancer, particularly stomach cancer.
March, China's first gastric cancer immunotherapy drug, Odivo (Navuliyu monoanti), was approved to treat patients with advanced stomach cancer who had previously received more than two treatments; 49 came the good news, Navuliyu single anti-combination chemotherapy for advanced gastric cancer first-line treatment success, compared with the current standard treatment of chemotherapy, significantly improved the survival benefits of patients, this is the first major breakthrough in the field of advanced gastric cancer first-line treatment in the past decade.
Referring to the CheckMate-649 study, professor Shen Lin, the lead Chinese researcher on the study, made no secret of his excitement: "Such tangible results and data are sure to change the landscape of first-line treatment for stomach cancer across the globe and will undoubtedly form the basis of our important treatment guidelines."
" Medical Valley.com Source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medical, and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here